featured
Lenalidomide and Dexamethasone ± Ixazomib Maintenance Tailored to Residual Disease Status in Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT IXAZOMIB MAINTENANCE TAILORED BY RESIDUAL DISEASE STATUS IN MYELOMA
Blood 2023 Jul 28;[EPub Ahead of Print], L Rosiñol, A Oriol, R Ríos-Tamayo, MJ Blanchard, I Jarque, J Bargay, MT Hernandez Garcia, V Cabañas, E Carrillo-Cruz, A Sureda, J Martinez-Lopez, I Krsnik, ME Gonzalez, LF Casado Montero, JM Marti, C Encinas, F de Arriba, L Palomera, A Sampol, Y Gonzalez-Montes, E Cabezudo, B Paiva, N Puig, MT Cedena, J de la Cruz, MV Mateos, J San-Miguel, JJ Lahuerta, J BladéFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.